Ubs Asset Management Americas Inc Arcus Biosciences, Inc. Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 173,598 shares of RCUS stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,598

Previous 97,423 78.19%

Holding current value

$2.51 Million

Previous $764,000 84.95%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$6.87 - $10.03 $523,322 - $764,035	76,175 Added 78.19%	173,598 $1.41 Million
Q1 2025 May 19, 2025	BUY	$7.85 - $15.24 $277,960 - $539,633	35,409 Added 57.1%	97,423 $764,000
Q4 2024 Feb 14, 2025	SELL	$14.28 - $18.44 $112,412 - $145,159	-7,872 Reduced 11.26%	62,014 $923,000
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $369,164 - $485,657	-26,966 Reduced 27.84%	69,886 $1.07 Million
Q2 2024 Aug 13, 2024	SELL	$14.59 - $18.48 $4.1 Million - $5.2 Million	-281,211 Reduced 74.38%	96,852 $1.48 Million
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $305,542 - $415,768	-20,603 Reduced 5.17%	378,063 $7.14 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $99,126 - $144,889	-7,381 Reduced 1.82%	398,666 $7.61 Million
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $92,557 - $123,655	-5,253 Reduced 1.28%	406,047 $7.29 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $152,114 - $220,642	9,531 Added 2.37%	411,300 $7.5 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $885,810 - $1.61 Million	-44,965 Reduced 10.07%	401,769 $8.31 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $88,761 - $114,897	-3,821 Reduced 0.85%	446,734 $11.7 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $2.36 Million - $5.16 Million	136,717 Added 43.56%	450,555 $11.4 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $2.1 Million - $3.04 Million	72,627 Added 30.11%	313,838 $9.9 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $6.26 Million - $9.68 Million	199,634 Added 480.15%	241,211 $9.76 Million
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $122,720 - $171,707	4,557 Added 12.31%	41,577 $1.45 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $82,673 - $129,988	3,634 Added 10.88%	37,020 $1.02 Million
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $113,246 - $179,177	-4,329 Reduced 11.48%	33,386 $937,000
Q4 2020 Mar 01, 2021	BUY	$17.0 - $32.36 $253,555 - $482,649	14,915 Added 65.42%	37,715 $979,000
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $137,377 - $204,142	-8,015 Reduced 26.01%	22,800 $390,000
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $430,485 - $1.13 Million	30,815 New	30,815 $762,000
Q2 2018 Aug 14, 2018	SELL	$12.24 - $17.05 $509,820 - $710,166	-41,652 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$15.44 - $17.71 $643,106 - $737,656	41,652 New	41,652 $0

Others Institutions Holding RCUS

# of Institutions

208

Shares Held

67M

Call Options Held

3.18M

Put Options Held

167K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.04B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Arcus Biosciences, Inc. Transaction History